PROM1 and hepatocellular carcinoma: To further evaluate the CSC-targeting effects of C504244, we sorted Huh7 cells into CD133+ (HCC stem cells) and CD133- (non-stem cells) subpopulations (26–28) and treated them with vehicle control or C504244 at indicated dosages.